Loading...
•
Jun 30, 2022
Praxis Q2 2022 Earnings Report
Praxis Precision Medicines reported financial results for the second quarter of 2022 and provided a corporate update.
Key Takeaways
Praxis Precision Medicines reported a net loss of $60.2 million for the second quarter of 2022. As of June 30, 2022, the company's cash, cash equivalents, and marketable securities totaled $165.4 million, expected to fund operations into the first quarter of 2024.
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22.
Primary endpoint for PRAX-944 Phase 2b Essential1 Study updated to efficacy.
PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window.
Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...